Eris Lifesciences to Transfer 100% Stake in Subsidiaries to Eris Therapeutics

Eris Lifesciences Limited, a leading Indian pharmaceutical company, has reorganised its holdings by transferring 100% of its shares in 2 subsidiaries—Eris Oaknet Healthcare Private Limited (EOHPL) and Aprica Healthcare Limited (AHL)—to Eris Therapeutics Limited (ETL), a fully owned subsidiary.  

“As a part of Eris Groups’ internal structuring of the holdings, the Company has transferred 100% of its holdings in the below mentioned entities to Eris Therapeutics Limited (“ETL”), a wholly-owned subsidiary: Eris Oaknet Healthcare Private Limited (“EOHPL”), wholly-owned subsidiary Aprica Healthcare Limited (“AHL”), wholly-owned subsidiary,” Eris Lifesciences said in filing.

Financial Impact

• Aprica Healthcare Limited (AHL): Contributed ₹604.05 million in revenue (3.0%) and had a net worth of ₹805.75 million (2.5%) in the last financial year.  

• Eris Oaknet Healthcare Private Limited (EOHPL): Contributed ₹726.47 million in revenue (3.6%) and had a net worth of ₹633.33 million (2.0%).  

Transaction Details

• Agreement Date: March 6, 2025  

• Expected Completion: March 31, 2025   
• Total transaction value: ₹862 crore.  

About the Company 

Eris Lifesciences, founded in 2007, is a publicly listed pharma company specialising in chronic and lifestyle-related treatments. With a plant in Guwahati and a nationwide network, it focuses on advanced science, patient care and specialist doctors. Key areas include diabetes, cardiac care, CNS and nutrition. It specialises in the production and distribution of generic pharmaceuticals, offering a diverse portfolio of oral dosage forms like capsules, tablets, and sachets across chronic and acute therapeutic areas.

Share Performance 

As of March 07, 2025, at 9:30 AM, the shares of Eris Lifesciences Ltd are trading at ₹1,274.10 per share, reflecting a surge of 0.35% from the previous day’s closing price. Over the past month, the stock has registered a loss of 13.85%. The stock’s 52-week high stands at ₹1,593.90 per share, while its low is ₹809.15 per share.

Conclusion

This transfer streamlines Eris Lifesciences’ operations, enhances efficiency and strengthens subsidiary management, positioning the company for growth and innovation.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.